Saeeda Almarzooqi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Saeeda Almarzooqi has a total of 114 co-authors. Here are the top co-authors by number of shared publications:
- Alia Albawardi
Department of Pathology, College of Medicine and Health Sciences, United Arab Emirates University, Al Ain P.O. Box 64141, United Arab Emirates
14 shared publications - Abdul-Kader Souid
United Arab Emirates University, UAE
10 shared publications - Sandeep B. Subramanya
Department of Physiology, College of Medicine and Health Sciences, United Arab Emirates University, Al Ain P.O. Box 15551, United Arab Emirates
9 shared publications - Shreesh Ojha
Department of Pharmacology and Therapeutics, College of Medicine and Health Sciences United Arab Emirates University Al Ain UAE
7 shared publications - Balaji Venkataraman
Department of Physiology, College of Medicine and Health Sciences, United Arab Emirates University, Al Ain P.O. Box 15551, United Arab Emirates
6 shared publications - Thomas Edward Adrian
Department of Basic Medical Sciences, College of Medicine, Mohammed Bin Rashid University of Medicine and Health Sciences, Dubai P.O. Box 505055, United Arab Emirates
6 shared publications
Latest Publications
- Open Access
- 21 January 2026
- Published by F1000 Research Ltd in F1000Research
- Vol. 13, 1539
Factors affecting women scientists’ retention and progress in STEM fields in the UAE: A cross-sectional study
Background The representation of women in science, technology, engineering, and mathematics (STEM) is disproportionate to graduates from STEM fields. There is limited research addressing challenges facing women’s retention in STEM in the UAE. Methods A cross-sectional study using a validated questionnaire was conducted. A total of 165 participants were enrolled; 62% males and 35% females. Results More women believed there is gender inequality in STEM (47% versus 28%). 44% of female participants experienced gender inequality in their careers. Men were significantly less likely to experience gender inequality (OR=0.06, 95% CI=0.02-0.16). Women reported lack of organizational emphasis on diversity and inclusion for promotion to leadership (44% versus 60%). Thematic analysis of open-ended responses showed a number of dominant barriers, such as gender bias in hiring and promotion, career impact of motherhood and family responsibilities, and lack of institutional support and flexibility. Conclusion Data confirms gender-based preconceptions and biases in STEM fields. Institutional initiatives and policies to challenge stereotypes and promote gender equality are required. The governmental role is crucial in creating an inclusive environment for women scientists.
- 21 January 2026
- Published by F1000 Research Ltd in F1000Research
- Vol. 13, 1539
Open AccessFactors affecting women scientists’ retention and progress in STEM fields in the UAE: A cross-sectional study
Background The representation of women in science, technology, engineering, and mathematics (STEM) is disproportionate to graduates from STEM fields. There is limited research addressing challenges facing women’s retention in STEM in the UAE. Methods A cross-sectional study using a validated questionnaire was conducted. A total of 165 participants were enrolled; 62% males and 35% females. Results More women believed there is gender inequality in STEM (47% versus 28%). 44% of female participants experienced gender inequality in their careers. Men were significantly less likely to experience gender inequality (OR=0.06, 95% CI=0.02-0.16). Women reported lack of organizational emphasis on diversity and inclusion for promotion to leadership (44% versus 60%). Thematic analysis of open-ended responses showed a number of dominant barriers, such as gender bias in hiring and promotion, career impact of motherhood and family responsibilities, and lack of institutional support and flexibility. Conclusion Data confirms gender-based preconceptions and biases in STEM fields. Institutional initiatives and policies to challenge stereotypes and promote gender equality are required. The governmental role is crucial in creating an inclusive environment for women scientists.
- Open Access
- 21 October 2025
- Published by F1000 Research Ltd in F1000Research
- Vol. 13, 1539
Factors affecting women scientists’ retention and progress in STEM fields in the UAE: A cross-sectional study
Background The representation of women in science, technology, engineering, and mathematics (STEM) is disproportionate to graduates from STEM fields. There is limited research addressing challenges facing women retention in STEM in the UAE. Methods A cross-sectional study using a validated questionnaire was conducted. A total of 165 participants were enrolled; 62% males and 35% females. Results More women believed there is gender inequality in STEM (47% versus 28%). 44% of female participants experienced gender inequality in their career. Men were significantly less likely to experience gender inequality (OR=0.06, 95% CI=0.02-0.16). Women reported lack of organizational emphasis on diversity and inclusion for promotion to leadership (44% versus 60%). Conclusion Data confirms gender-based preconceptions and biases in STEM fields. Institutional initiatives and policies to challenge stereotypes and promote gender equality are required. Governmental role is crucial in creating an inclusive environment for women scientists.
- 21 October 2025
- Published by F1000 Research Ltd in F1000Research
- Vol. 13, 1539
Open AccessFactors affecting women scientists’ retention and progress in STEM fields in the UAE: A cross-sectional study
Background The representation of women in science, technology, engineering, and mathematics (STEM) is disproportionate to graduates from STEM fields. There is limited research addressing challenges facing women retention in STEM in the UAE. Methods A cross-sectional study using a validated questionnaire was conducted. A total of 165 participants were enrolled; 62% males and 35% females. Results More women believed there is gender inequality in STEM (47% versus 28%). 44% of female participants experienced gender inequality in their career. Men were significantly less likely to experience gender inequality (OR=0.06, 95% CI=0.02-0.16). Women reported lack of organizational emphasis on diversity and inclusion for promotion to leadership (44% versus 60%). Conclusion Data confirms gender-based preconceptions and biases in STEM fields. Institutional initiatives and policies to challenge stereotypes and promote gender equality are required. Governmental role is crucial in creating an inclusive environment for women scientists.
- Open Access
- 1 September 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (17) , 8493
β-Caryophyllene Ameliorates Thioacetamide-Induced Liver Fibrosis in Rats: A Preventative Approach
Liver fibrosis is associated with increased rates of morbidity and mortality. At present, there are no specific treatments that can directly reverse hepatic fibrosis. The endocannabinoid system has been found to play a significant role in regulating the development and progression of liver diseases, in addition to having protective effects. In this study, we investigate the protective potential of β-Caryophyllene (BCP) against Thioacetamide (TAA)-induced liver fibrosis. Wistar rats were injected with TAA (200 mg/kg) three times per week for 8 weeks to induce liver fibrosis. They also received oral BCP before the TAA injections. AM630 (1 mg/kg) was administered to confirm the CB2 receptor-dependent effect of BCP. The BCP treatment (50 mg/kg) protected against cell injury and potentiated antioxidant defense by replenishing hepatic GSH, improving catalase activity, and inhibiting the formation of MDA. The co-administration of BCP mitigated the TAA-induced inflammatory response by decreasing the release of proinflammatory cytokines. Histological examination showed preserved cellular integrity, decreased collagen deposits with other extracellular matrix proteins, and low levels of myofibroblast activation. In addition, the BCP-treated rats demonstrated upregulated sirtuin 1 (SIRT1) expression, which had a direct inhibitory effect on hypoxia inducible factor (HIF-1α). AM630 pre-treatment inhibited all the aforementioned protective mechanisms of BCP. Based on our findings, BCP exerts protective effects in liver fibrosis, which can be attributed to its agonist action on CB2 receptors. This study provides preclinical evidence of the potential preventative benefits of BCP in liver fibrosis.
- 1 September 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (17) , 8493
Open Accessβ-Caryophyllene Ameliorates Thioacetamide-Induced Liver Fibrosis in Rats: A Preventative Approach
Liver fibrosis is associated with increased rates of morbidity and mortality. At present, there are no specific treatments that can directly reverse hepatic fibrosis. The endocannabinoid system has been found to play a significant role in regulating the development and progression of liver diseases, in addition to having protective effects. In this study, we investigate the protective potential of β-Caryophyllene (BCP) against Thioacetamide (TAA)-induced liver fibrosis. Wistar rats were injected with TAA (200 mg/kg) three times per week for 8 weeks to induce liver fibrosis. They also received oral BCP before the TAA injections. AM630 (1 mg/kg) was administered to confirm the CB2 receptor-dependent effect of BCP. The BCP treatment (50 mg/kg) protected against cell injury and potentiated antioxidant defense by replenishing hepatic GSH, improving catalase activity, and inhibiting the formation of MDA. The co-administration of BCP mitigated the TAA-induced inflammatory response by decreasing the release of proinflammatory cytokines. Histological examination showed preserved cellular integrity, decreased collagen deposits with other extracellular matrix proteins, and low levels of myofibroblast activation. In addition, the BCP-treated rats demonstrated upregulated sirtuin 1 (SIRT1) expression, which had a direct inhibitory effect on hypoxia inducible factor (HIF-1α). AM630 pre-treatment inhibited all the aforementioned protective mechanisms of BCP. Based on our findings, BCP exerts protective effects in liver fibrosis, which can be attributed to its agonist action on CB2 receptors. This study provides preclinical evidence of the potential preventative benefits of BCP in liver fibrosis.
- 23 October 2024
- Published by SAGE Publications in Pediatric and Developmental Pathology
- Vol. 28 (1) , 74-77
Hereditary Multiple Intestinal Atresia With a Novel TTC7A Pathogenic Variant: Gastrointestinal Manifestations in Two Cases
Hereditary multiple intestinal atresia (HMIA) with TTC7A mutation is caused by homozygous or compound heterozygous TTC7A gene mutation. It is characterized by multiple small and large intestinal atresias and/or stenoses. TTC7A mutation is described in some patients with inflammatory bowel disease and mild-severe forms of severe combined immunodeficiency without intestinal atresia or stenosis. We present 2 cases of intestinal atresia and documented TTC7A mutation with a novel variant. Both cases had different clinical and pathological manifestations. The first case is a male infant born at 35 weeks of gestation with failure to pass meconium. Intestinal biopsy reveals apoptotic enteropathy with villous atrophy and increased mucosal eosinophils. The second case is referred at birth for antenatally detected umbilical hernia, polyhydramnios and possible upper intestinal obstruction. The resected specimen reveals ileal atresia with partial villous atrophy, decreased number of lamina propria inflammatory cells and absence of plasma cells. In conclusion, these cases reflect an emerging TTC7A pathogenic variant with different histological manifestations and leads to characterization as immune dysregulation disorder. There is a need to differentiate TTC7A mutation associated ones from cases labeled as very early onset IBD and rule out other hereditary immunodeficiencies.
- 23 October 2024
- Published by SAGE Publications in Pediatric and Developmental Pathology
- Vol. 28 (1) , 74-77
Hereditary Multiple Intestinal Atresia With a Novel TTC7A Pathogenic Variant: Gastrointestinal Manifestations in Two Cases
Hereditary multiple intestinal atresia (HMIA) with TTC7A mutation is caused by homozygous or compound heterozygous TTC7A gene mutation. It is characterized by multiple small and large intestinal atresias and/or stenoses. TTC7A mutation is described in some patients with inflammatory bowel disease and mild-severe forms of severe combined immunodeficiency without intestinal atresia or stenosis. We present 2 cases of intestinal atresia and documented TTC7A mutation with a novel variant. Both cases had different clinical and pathological manifestations. The first case is a male infant born at 35 weeks of gestation with failure to pass meconium. Intestinal biopsy reveals apoptotic enteropathy with villous atrophy and increased mucosal eosinophils. The second case is referred at birth for antenatally detected umbilical hernia, polyhydramnios and possible upper intestinal obstruction. The resected specimen reveals ileal atresia with partial villous atrophy, decreased number of lamina propria inflammatory cells and absence of plasma cells. In conclusion, these cases reflect an emerging TTC7A pathogenic variant with different histological manifestations and leads to characterization as immune dysregulation disorder. There is a need to differentiate TTC7A mutation associated ones from cases labeled as very early onset IBD and rule out other hereditary immunodeficiencies.
- Open Access
- 13 September 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (18) , 14013
α-Bisabolol, a Dietary Sesquiterpene, Attenuates Doxorubicin-Induced Acute Cardiotoxicity in Rats by Inhibiting Cellular Signaling Pathways, Nrf2/Keap-1/HO-1, Akt/mTOR/GSK-3β, NF-κB/p38/MAPK, and NLRP3 Inflammasomes Regulating Oxidative Stress and Inflammatory Cascades
Cancer chemotherapy with doxorubicin (DOX) may have multiorgan toxicities including cardiotoxicity, and this is one of the major limitations of its clinical use. The present study aimed to evaluate the cardioprotective role of α-Bisabolol (BSB) in DOX-induced acute cardiotoxicity in rats and the underlying pharmacological and molecular mechanisms. DOX (12.5 mg/kg, single dose) was injected intraperitoneally into the rats for induction of acute cardiotoxicity. BSB was given orally to rats (25 mg/kg, p.o. twice daily) for a duration of five days. DOX administration induced cardiac dysfunction as evidenced by altered body weight, hemodynamics, and release of cardio-specific diagnostic markers. The occurrence of oxidative stress was evidenced by a significant decline in antioxidant defense along with a rise in lipid peroxidation and hyperlipidemia. Additionally, DOX also increased the levels and expression of proinflammatory cytokines and inflammatory mediators, as well as activated NF-κB/MAPK signaling in the heart, following alterations in the Nrf2/Keap-1/HO-1 and Akt/mTOR/GSK-3β signaling. DOX also perturbed NLRP3 inflammasome activation-mediated pyroptosis in the myocardium of rats. Furthermore, histopathological studies revealed cellular alterations in the myocardium. On the contrary, treatment with BSB has been observed to preserve the myocardium and restore all the cellular, molecular, and structural perturbations in the heart tissues of DOX-induced cardiotoxicity in rats. Results of the present study clearly demonstrate the protective role of BSB against DOX-induced cardiotoxicity, which is attributed to its potent antioxidant, anti-inflammatory, and antihyperlipidemic effects resulting from favorable modulation of numerous cellular signaling regulatory pathways, viz., Nrf2/Keap-1/HO-1, Akt/mTOR/GSK-3β, NF-κB/p38/MAPK, and NLRP3 inflammasomes, in countering the cascades of oxidative stress and inflammation. The observations suggest that BSB can be a promising agent or an adjuvant to limit the cardiac injury caused by DOX. Further studies including the role in tumor-bearing animals as well as regulatory toxicology are suggested.
- 13 September 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (18) , 14013
Open Accessα-Bisabolol, a Dietary Sesquiterpene, Attenuates Doxorubicin-Induced Acute Cardiotoxicity in Rats by Inhibiting Cellular Signaling Pathways, Nrf2/Keap-1/HO-1, Akt/mTOR/GSK-3β, NF-κB/p38/MAPK, and NLRP3 Inflammasomes Regulating Oxidative Stress and Inflammatory Cascades
Cancer chemotherapy with doxorubicin (DOX) may have multiorgan toxicities including cardiotoxicity, and this is one of the major limitations of its clinical use. The present study aimed to evaluate the cardioprotective role of α-Bisabolol (BSB) in DOX-induced acute cardiotoxicity in rats and the underlying pharmacological and molecular mechanisms. DOX (12.5 mg/kg, single dose) was injected intraperitoneally into the rats for induction of acute cardiotoxicity. BSB was given orally to rats (25 mg/kg, p.o. twice daily) for a duration of five days. DOX administration induced cardiac dysfunction as evidenced by altered body weight, hemodynamics, and release of cardio-specific diagnostic markers. The occurrence of oxidative stress was evidenced by a significant decline in antioxidant defense along with a rise in lipid peroxidation and hyperlipidemia. Additionally, DOX also increased the levels and expression of proinflammatory cytokines and inflammatory mediators, as well as activated NF-κB/MAPK signaling in the heart, following alterations in the Nrf2/Keap-1/HO-1 and Akt/mTOR/GSK-3β signaling. DOX also perturbed NLRP3 inflammasome activation-mediated pyroptosis in the myocardium of rats. Furthermore, histopathological studies revealed cellular alterations in the myocardium. On the contrary, treatment with BSB has been observed to preserve the myocardium and restore all the cellular, molecular, and structural perturbations in the heart tissues of DOX-induced cardiotoxicity in rats. Results of the present study clearly demonstrate the protective role of BSB against DOX-induced cardiotoxicity, which is attributed to its potent antioxidant, anti-inflammatory, and antihyperlipidemic effects resulting from favorable modulation of numerous cellular signaling regulatory pathways, viz., Nrf2/Keap-1/HO-1, Akt/mTOR/GSK-3β, NF-κB/p38/MAPK, and NLRP3 inflammasomes, in countering the cascades of oxidative stress and inflammation. The observations suggest that BSB can be a promising agent or an adjuvant to limit the cardiac injury caused by DOX. Further studies including the role in tumor-bearing animals as well as regulatory toxicology are suggested.
- Open Access
- 18 May 2023
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 385 (S3) , 303
β-caryophyllene, a CB2 Receptor Agonist Alleviates Diabetic Cardiomyopathy via Inhibiting AGE/RAGE-Induced Oxidative Stress, Fibrosis, and Inflammasome Activation
ID 14617 Poster Board 303 Chronic hyperglycemia-induced advanced glycation end products-receptor for advanced glycation end products (AGE-RAGE) following activation results in the oxidative stress, inflammasome activation, and tissue fibrosis and plays important role in the development and progression of diabetic cardiomyopathy (DCM). Provided the emerging role of cannabinoid type 2 receptors (CB2) in diabetes and its complications, the present study aimed to investigate the role of CB2 receptor activation in murine model of DCM by its agonist β-caryophyllene (BCP), a dietary phytocannabinoid. The study also investigated underlying signaling pathways. The experimental murine model of DCM was induced by feeding high fat diet (45% fat) for four weeks in addition to single intraperitoneal injection of streptozotocin (100 mg/kg/body weight). Following the development of diabetes, animals were orally treated with BCP (50 mg/kg/body weight) for 12 weeks. In one group to demonstrate CB2 receptor specific properties of BCP, AM630 (1.5 mg/kg), a specific CB2 receptor antagonist, was given 30 min prior to BCP treatment. At the end of the experiments, metabolic, histopathological, immunohistochemical, electron microscopic and western blotting were performed to evaluate efficacy and demonstrate mechanism. The results revealed that treatment with BCP significantly improved glucose tolerance, enhanced serum insulin level along with reducing insulin resistance. BCP restored phosphorylation of cardiac contractile protein troponin I. BCP was observed to enhance PI3K/AKT phosphorylation, reduce expression of Keap1 which upregulated antioxidant enzymes (HO1, SOD2) mediated by stimulation of Nrf2 signaling. The AGE-RAGE signaling pathway in the heart of DCM mice was significantly mitigated by BCP treatment evidenced by reduced expression of AGEs, RAGE and NOX4. Additionally, NLRP3 inflammasome activation was downregulated and expression of ASC, pro-caspase1 was significantly reduced which further decreased IL-1β and IL-18 expression. The H&E, Masson’s trichome, and transmission electron microscopy results further supported the finding that BCP mitigated cardiac hypertrophy, collagen deposition, myofilament disarrangement, mitochondrial disruption, thickened capillary basement membrane, and increased nuclear membrane invaginations. Furthermore, BCP suppressed endothelial-to-mesenchymal transition (EndMT) in DCM mice hearts revealed by decreased expression levels of fibroblast markers (α-SMA, vimentin, and collagen I) and increased expression levels of endothelial markers (CD31 and VE-cadherin). Interestingly, pre-administration of AM630 abrogated the positive effects of BCP in DCM mice. Collectively, these results demonstrate that inhibition of AGE/RAGE by BCP treatment to DCM mice rescues against diabetes associated complications by reducing oxidative damage, fibrosis, and inflammasome activation attributed to upregulation of PI3K/AKT/Nrf2 signaling, repression of EndMT transition, and inhibition of NLRP3 inflammasome activation in a CB2 receptor dependent mechanism. The study results suggest that CB2 receptors activation may be a vital therapeutic avenue for diabetic cardiomyopathy and BCP could be a novel agent of natural origin with a rationale based on pharmacological and molecular mechanisms for its use as therapeutic and nutraceutical agent.
- 18 May 2023
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 385 (S3) , 303
Open Accessβ-caryophyllene, a CB2 Receptor Agonist Alleviates Diabetic Cardiomyopathy via Inhibiting AGE/RAGE-Induced Oxidative Stress, Fibrosis, and Inflammasome Activation
ID 14617 Poster Board 303 Chronic hyperglycemia-induced advanced glycation end products-receptor for advanced glycation end products (AGE-RAGE) following activation results in the oxidative stress, inflammasome activation, and tissue fibrosis and plays important role in the development and progression of diabetic cardiomyopathy (DCM). Provided the emerging role of cannabinoid type 2 receptors (CB2) in diabetes and its complications, the present study aimed to investigate the role of CB2 receptor activation in murine model of DCM by its agonist β-caryophyllene (BCP), a dietary phytocannabinoid. The study also investigated underlying signaling pathways. The experimental murine model of DCM was induced by feeding high fat diet (45% fat) for four weeks in addition to single intraperitoneal injection of streptozotocin (100 mg/kg/body weight). Following the development of diabetes, animals were orally treated with BCP (50 mg/kg/body weight) for 12 weeks. In one group to demonstrate CB2 receptor specific properties of BCP, AM630 (1.5 mg/kg), a specific CB2 receptor antagonist, was given 30 min prior to BCP treatment. At the end of the experiments, metabolic, histopathological, immunohistochemical, electron microscopic and western blotting were performed to evaluate efficacy and demonstrate mechanism. The results revealed that treatment with BCP significantly improved glucose tolerance, enhanced serum insulin level along with reducing insulin resistance. BCP restored phosphorylation of cardiac contractile protein troponin I. BCP was observed to enhance PI3K/AKT phosphorylation, reduce expression of Keap1 which upregulated antioxidant enzymes (HO1, SOD2) mediated by stimulation of Nrf2 signaling. The AGE-RAGE signaling pathway in the heart of DCM mice was significantly mitigated by BCP treatment evidenced by reduced expression of AGEs, RAGE and NOX4. Additionally, NLRP3 inflammasome activation was downregulated and expression of ASC, pro-caspase1 was significantly reduced which further decreased IL-1β and IL-18 expression. The H&E, Masson’s trichome, and transmission electron microscopy results further supported the finding that BCP mitigated cardiac hypertrophy, collagen deposition, myofilament disarrangement, mitochondrial disruption, thickened capillary basement membrane, and increased nuclear membrane invaginations. Furthermore, BCP suppressed endothelial-to-mesenchymal transition (EndMT) in DCM mice hearts revealed by decreased expression levels of fibroblast markers (α-SMA, vimentin, and collagen I) and increased expression levels of endothelial markers (CD31 and VE-cadherin). Interestingly, pre-administration of AM630 abrogated the positive effects of BCP in DCM mice. Collectively, these results demonstrate that inhibition of AGE/RAGE by BCP treatment to DCM mice rescues against diabetes associated complications by reducing oxidative damage, fibrosis, and inflammasome activation attributed to upregulation of PI3K/AKT/Nrf2 signaling, repression of EndMT transition, and inhibition of NLRP3 inflammasome activation in a CB2 receptor dependent mechanism. The study results suggest that CB2 receptors activation may be a vital therapeutic avenue for diabetic cardiomyopathy and BCP could be a novel agent of natural origin with a rationale based on pharmacological and molecular mechanisms for its use as therapeutic and nutraceutical agent.
- Open Access
Cis-Nerolidol Inhibits MAP Kinase and NF-κB Signaling Pathways and Prevents Epithelial Tight Junction Dysfunction in Colon Inflammation: In Vivo and In Vitro Studies
Inflammation of the GI tract leads to compromised epithelial barrier integrity, which increases intestine permeability. A compromised intestinal barrier is a critical event that leads to microbe entry and promotes inflammatory responses. Inflammatory bowel diseases that comprise Crohn’s disease (CD) and ulcerative colitis (UC) show an increase in intestinal permeability. Nerolidol (NED), a naturally occurring sesquiterpene alcohol, has potent anti-inflammatory properties in preclinical models of colon inflammation. In this study, we investigated the effect of NED on MAPKs, NF-κB signaling pathways, and intestine epithelial tight junction physiology using in vivo and in vitro models. The effect of NED on proinflammatory cytokine release and MAPK and NF-κB signaling pathways were evaluated using lipopolysaccharides (LPS)-stimulated RAW 264.7 macrophages. Subsequently, the role of NED on MAPKs, NF-κB signaling, and the intestine tight junction integrity were assessed using DSS-induced colitis and LPS-stimulated Caco-2 cell culture models. Our result indicates that NED pre-treatment significantly inhibited proinflammatory cytokine release, expression of proteins involved in MAP kinase, and NF-κB signaling pathways in LPS-stimulated RAW macrophages and DSS-induced colitis. Furthermore, NED treatment significantly decreased FITC-dextran permeability in DSS-induced colitis. NED treatment enhanced tight junction protein expression (claudin-1, 3, 7, and occludin). Time-dependent increases in transepithelial electrical resistance (TEER) measurements reflect the formation of healthy tight junctions in the Caco-2 monolayer. LPS-stimulated Caco-2 showed a significant decrease in TEER. However, NED pre-treatment significantly prevented the fall in TEER measurements, indicating its protective role. In conclusion, NED significantly decreased MAPK and NF-κB signaling pathways and decreased tight junction permeability by enhancing epithelial tight junction protein expression.
Open AccessCis-Nerolidol Inhibits MAP Kinase and NF-κB Signaling Pathways and Prevents Epithelial Tight Junction Dysfunction in Colon Inflammation: In Vivo and In Vitro Studies
Inflammation of the GI tract leads to compromised epithelial barrier integrity, which increases intestine permeability. A compromised intestinal barrier is a critical event that leads to microbe entry and promotes inflammatory responses. Inflammatory bowel diseases that comprise Crohn’s disease (CD) and ulcerative colitis (UC) show an increase in intestinal permeability. Nerolidol (NED), a naturally occurring sesquiterpene alcohol, has potent anti-inflammatory properties in preclinical models of colon inflammation. In this study, we investigated the effect of NED on MAPKs, NF-κB signaling pathways, and intestine epithelial tight junction physiology using in vivo and in vitro models. The effect of NED on proinflammatory cytokine release and MAPK and NF-κB signaling pathways were evaluated using lipopolysaccharides (LPS)-stimulated RAW 264.7 macrophages. Subsequently, the role of NED on MAPKs, NF-κB signaling, and the intestine tight junction integrity were assessed using DSS-induced colitis and LPS-stimulated Caco-2 cell culture models. Our result indicates that NED pre-treatment significantly inhibited proinflammatory cytokine release, expression of proteins involved in MAP kinase, and NF-κB signaling pathways in LPS-stimulated RAW macrophages and DSS-induced colitis. Furthermore, NED treatment significantly decreased FITC-dextran permeability in DSS-induced colitis. NED treatment enhanced tight junction protein expression (claudin-1, 3, 7, and occludin). Time-dependent increases in transepithelial electrical resistance (TEER) measurements reflect the formation of healthy tight junctions in the Caco-2 monolayer. LPS-stimulated Caco-2 showed a significant decrease in TEER. However, NED pre-treatment significantly prevented the fall in TEER measurements, indicating its protective role. In conclusion, NED significantly decreased MAPK and NF-κB signaling pathways and decreased tight junction permeability by enhancing epithelial tight junction protein expression.
- Open Access
- 24 March 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (7) , 6160
Molecular Docking Identifies 1,8-Cineole (Eucalyptol) as A Novel PPARγ Agonist That Alleviates Colon Inflammation
Inflammatory bowel disease, comprising Crohn’s disease (CD) and ulcerative colitis (UC), is often debilitating. The disease etiology is multifactorial, involving genetic susceptibility, microbial dysregulation, abnormal immune activation, and environmental factors. Currently, available drug therapies are associated with adverse effects when used long-term. Therefore, the search for new drug candidates to treat IBD is imperative. The peroxisome proliferator-activated receptor-γ (PPARγ) is highly expressed in the colon. PPARγ plays a vital role in regulating colonic inflammation. 1,8-cineole, also known as eucalyptol, is a monoterpene oxide present in various aromatic plants which possess potent anti-inflammatory activity. Molecular docking and dynamics studies revealed that 1,8-cineole binds to PPARγ and if it were an agonist, that would explain the anti-inflammatory effects of 1,8-cineole. Therefore, we investigated the role of 1,8-cineole in colonic inflammation, using both in vivo and in vitro experimental approaches. Dextran sodium sulfate (DSS)-induced colitis was used as the in vivo model, and tumor necrosis factor-α (TNFα)-stimulated HT-29 cells as the in vitro model. 1,8-cineole treatment significantly decreased the inflammatory response in DSS-induced colitis mice. 1,8-cineole treatment also increased nuclear factor erythroid 2-related factor 2 (Nrf2) translocation into the nucleus to induce potent antioxidant effects. 1,8-cineole also increased colonic PPARγ protein expression. Similarly, 1,8-cineole decreased proinflammatory chemokine production and increased PPARγ protein expression in TNFα-stimulated HT-29 cells. 1,8-cineole also increased PPARγ promoter activity time-dependently. Because of its potent anti-inflammatory effects, 1,8-cineole may be valuable in treating IBD.
- 24 March 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (7) , 6160
Open AccessMolecular Docking Identifies 1,8-Cineole (Eucalyptol) as A Novel PPARγ Agonist That Alleviates Colon Inflammation
Inflammatory bowel disease, comprising Crohn’s disease (CD) and ulcerative colitis (UC), is often debilitating. The disease etiology is multifactorial, involving genetic susceptibility, microbial dysregulation, abnormal immune activation, and environmental factors. Currently, available drug therapies are associated with adverse effects when used long-term. Therefore, the search for new drug candidates to treat IBD is imperative. The peroxisome proliferator-activated receptor-γ (PPARγ) is highly expressed in the colon. PPARγ plays a vital role in regulating colonic inflammation. 1,8-cineole, also known as eucalyptol, is a monoterpene oxide present in various aromatic plants which possess potent anti-inflammatory activity. Molecular docking and dynamics studies revealed that 1,8-cineole binds to PPARγ and if it were an agonist, that would explain the anti-inflammatory effects of 1,8-cineole. Therefore, we investigated the role of 1,8-cineole in colonic inflammation, using both in vivo and in vitro experimental approaches. Dextran sodium sulfate (DSS)-induced colitis was used as the in vivo model, and tumor necrosis factor-α (TNFα)-stimulated HT-29 cells as the in vitro model. 1,8-cineole treatment significantly decreased the inflammatory response in DSS-induced colitis mice. 1,8-cineole treatment also increased nuclear factor erythroid 2-related factor 2 (Nrf2) translocation into the nucleus to induce potent antioxidant effects. 1,8-cineole also increased colonic PPARγ protein expression. Similarly, 1,8-cineole decreased proinflammatory chemokine production and increased PPARγ protein expression in TNFα-stimulated HT-29 cells. 1,8-cineole also increased PPARγ promoter activity time-dependently. Because of its potent anti-inflammatory effects, 1,8-cineole may be valuable in treating IBD.
- Open Access
- 8 January 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (2) , 1223
Effect of Sirolimus/Metformin Co-Treatment on Hyperglycemia and Cellular Respiration in BALB/c Mice
Sirolimus (SRL) is widely used as an immunosuppressant to prevent graft rejection, despite the risk of impairing glucose metabolism. Metformin (MET) can reduce the detrimental effects of SRL in many patients, including diabetes and renal transplant recipients. Limited in vivo studies have reported on SRL and MET therapy, particularly in relation to cellular bioenergetics, glucose metabolism, and insulin resistance. Herein, we investigated the efficacy of SRL and MET co-treatment in BALB/c mice over 4 weeks. Balb/c mice (4–6 weeks old) were divided into four groups and injected intraperitoneally (i.p.) with water (control, CTRL), MET (200 µg/g), SRL (5 µg/g), or MET (200 µg/g) +SRL (5 µg/g) over a period of one month. We evaluated the body weight, food consumption rate, random blood glucose (BG), insulin levels, serum biochemistry parameters (ALT, Albumin, BUN, Creatinine), and histomorphology in all groups using standardized techniques and assays. All drug-treated groups showed a statistically significant decrease in weight gain compared to the CTRL group, despite normal food intake. Treatment with SRL caused elevated BG and insulin levels, which were restored with SRL + MET combination. Serum biochemical parameters were within the normal range in all the studied groups. SRL+ MET co-treatment decreased liver cellular respiration and increased cellular ATP levels in the liver. In the pancreas, co-treatment resulted in increased cellular respiration and decreased cellular ATP levels. Liver and pancreatic histology were unchanged in all groups. This study showed that co-treatment of SRL with MET alleviates hyperglycemia induced by SRL without any deleterious effects. These results provide initial insights into the potential use of SRL + MET therapy in various settings.
- 8 January 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (2) , 1223
Open AccessEffect of Sirolimus/Metformin Co-Treatment on Hyperglycemia and Cellular Respiration in BALB/c Mice
Sirolimus (SRL) is widely used as an immunosuppressant to prevent graft rejection, despite the risk of impairing glucose metabolism. Metformin (MET) can reduce the detrimental effects of SRL in many patients, including diabetes and renal transplant recipients. Limited in vivo studies have reported on SRL and MET therapy, particularly in relation to cellular bioenergetics, glucose metabolism, and insulin resistance. Herein, we investigated the efficacy of SRL and MET co-treatment in BALB/c mice over 4 weeks. Balb/c mice (4–6 weeks old) were divided into four groups and injected intraperitoneally (i.p.) with water (control, CTRL), MET (200 µg/g), SRL (5 µg/g), or MET (200 µg/g) +SRL (5 µg/g) over a period of one month. We evaluated the body weight, food consumption rate, random blood glucose (BG), insulin levels, serum biochemistry parameters (ALT, Albumin, BUN, Creatinine), and histomorphology in all groups using standardized techniques and assays. All drug-treated groups showed a statistically significant decrease in weight gain compared to the CTRL group, despite normal food intake. Treatment with SRL caused elevated BG and insulin levels, which were restored with SRL + MET combination. Serum biochemical parameters were within the normal range in all the studied groups. SRL+ MET co-treatment decreased liver cellular respiration and increased cellular ATP levels in the liver. In the pancreas, co-treatment resulted in increased cellular respiration and decreased cellular ATP levels. Liver and pancreatic histology were unchanged in all groups. This study showed that co-treatment of SRL with MET alleviates hyperglycemia induced by SRL without any deleterious effects. These results provide initial insights into the potential use of SRL + MET therapy in various settings.
- Open Access
β-Myrcene Mitigates Colon Inflammation by Inhibiting MAP Kinase and NF-κB Signaling Pathways
Inflammatory bowel diseases (IBDs) are chronic inflammatory disorders that include Crohn’s disease (CD) and ulcerative colitis (UC). The incidence of IBD is rising globally. However, the etiology of IBD is complex and governed by multiple factors. The current clinical treatment for IBD mainly includes steroids, biological agents and need-based surgery, based on the severity of the disease. Current drug therapy is often associated with adverse effects, which limits its use. Therefore, it necessitates the search for new drug candidates. In this pursuit, phytochemicals take the lead in the search for drug candidates to benefit from IBD treatment. β-myrcene is a natural phytochemical compound present in various plant species which possesses potent anti-inflammatory activity. Here we investigated the role of β-myrcene on colon inflammation to explore its molecular targets. We used 2% DSS colitis and TNF-α challenged HT-29 adenocarcinoma cells as in vivo and in vitro models. Our result indicated that the administration of β-myrcene in dextran sodium sulfate (DSS)-treated mice restored colon length, decreased disease activity index (DAI), myeloperoxidase (MPO) enzyme activity and suppressed proinflammatory mediators. β-myrcene administration suppressed mitogen-activated protein kinases (MAPKs) and nuclear factor-κB (NF-κB) pathways to limit inflammation. β-myrcene also suppressed mRNA expression of proinflammatory chemokines in tumor necrosis factor-α (TNF-α) challenged HT-29 adenocarcinoma cells. In conclusion, β-myrcene administration suppresses colon inflammation by inhibiting MAP kinases and NF-κB pathways.
Open Accessβ-Myrcene Mitigates Colon Inflammation by Inhibiting MAP Kinase and NF-κB Signaling Pathways
Inflammatory bowel diseases (IBDs) are chronic inflammatory disorders that include Crohn’s disease (CD) and ulcerative colitis (UC). The incidence of IBD is rising globally. However, the etiology of IBD is complex and governed by multiple factors. The current clinical treatment for IBD mainly includes steroids, biological agents and need-based surgery, based on the severity of the disease. Current drug therapy is often associated with adverse effects, which limits its use. Therefore, it necessitates the search for new drug candidates. In this pursuit, phytochemicals take the lead in the search for drug candidates to benefit from IBD treatment. β-myrcene is a natural phytochemical compound present in various plant species which possesses potent anti-inflammatory activity. Here we investigated the role of β-myrcene on colon inflammation to explore its molecular targets. We used 2% DSS colitis and TNF-α challenged HT-29 adenocarcinoma cells as in vivo and in vitro models. Our result indicated that the administration of β-myrcene in dextran sodium sulfate (DSS)-treated mice restored colon length, decreased disease activity index (DAI), myeloperoxidase (MPO) enzyme activity and suppressed proinflammatory mediators. β-myrcene administration suppressed mitogen-activated protein kinases (MAPKs) and nuclear factor-κB (NF-κB) pathways to limit inflammation. β-myrcene also suppressed mRNA expression of proinflammatory chemokines in tumor necrosis factor-α (TNF-α) challenged HT-29 adenocarcinoma cells. In conclusion, β-myrcene administration suppresses colon inflammation by inhibiting MAP kinases and NF-κB pathways.